Clinical trials: Severe Insulin Resistance
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Nutritional and Metabolic Diseases, Inflammation
A Study of Strawberries and Disease Risk
The purpose of this study is to test whether compounds found in strawberries (polyphenolics which are typically found in berry products, tea, coffee, red wine, and chocolate) will help reduce insulin resistance and inflammation…
- Conditions
- Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
- Trial name
- STRB (NCT01199848)
- Testing
- 10G, 20G, 40G
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Metabolic Syndrome
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial…
- Trial name
- NCT02069717
- Testing
- Not applicable-observational study
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Diabetes Mellitus
BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance
The study is designed to compare meal time glucose control associated with BIOD-531, a rapidly absorbed concentrated insulin to that associated with Humalog Mix 75/25 and Humulin R U-500 in patients with diabetes and severe…
- Trial name
- NCT02324309
- Testing
- BIOD-531, Humalog Mix 75/25, Humulin R U-500
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Biodel
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia
- Trial name
- Pilot'Ex (NCT05221359)
- Testing
- ExOlin®, Insulin aspart
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Defymed